Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Announce Updated Data On IPI-504 to be Presented At American Society of Clinical Oncology

CAMBRIDGE, Mass. and GAITHERSBURG, Md., May 31, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that interim clinical data on IPI-504 in a Phase I trial in patients with gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas (STS), will be presented at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 1-5, 2007 at McCormick Place in Chicago, Ill. IPI-504, the companies' heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated as a water-soluble, intravenous formulation in two disease-focused clinical trials involving patients with GIST/STS and non-small cell lung cancer (NSCLC).